NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth

/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announces...

Related Keywords

France , United States , Americans , French , Stephen Willard , Nasdaq , Therapeutics Inc , Nrx Pharmaceuticals , Us National Institutes Of Health , Us Patient Centered Outcomes Research Initiative , Alvogen Inc , Nephron Pharmaceuticals , Lotus Pharmaceuticals Inc , Nrxp Nrx Pharmaceuticals , Prnewswire Nrx Pharmaceuticals Inc , Lotus , Specialty Pharmaceutical Company , Company Board Of Directors , Lotus Pharmaceuticals , Suicidal Bipolar Depression , Data Lock , Investigational New Drug , Chronic Pain , Complicated Urinary Tract , Centered Outcomes Research Initiative , Electroconvulsive Therapy , Severe Depression , New Drug Application , Acute Suicidality , Complicated Urinary Tract Infection , Qualified Infectious Disease Product , Fast Track , Priority Review , Chief Executive Officer , Urinary Tract Infection , Monday April , Breakthrough Therapy , Hope Therapeutics , Fast Track Designation ,